Chronic Kidney Disease (CKD) Support Protocol
Chronic Kidney Disease (CKD) Support Protocol framework focused on consistent execution, practical monitoring, and safer progression.
A nephroprotective protocol for patients with CKD stages 2–4, addressing progressive renal inflammation, anemia, muscle wasting (sarcopenia), peripheral neuropathy, and immune suppression through carefully selected peptides with renal safety profiles.
Who it's for
Use this as an educational framework with clinical oversight. Keep timing consistent, track response daily, and change one variable at a time after trend review. Pair protocol use with sleep, nutrition, and recovery fundamentals.
Free Peptide Guide
Chronic Kidney Disease (CKD) Support Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.
Protocol at a Glance
Cycle Duration
Ongoing; monitor GFR, creatinine, and CBC every 3 months; adjust doses with nephrology oversight
Target Audience
Adults with CKD stages 2–4 under nephrology care; use with caution in stage 5/dialysis patients
| Compound | Dose | Frequency |
|---|---|---|
| ARA-290 ARA-290: non-hematopoietic EPO receptor agonist; reduces renal tubular inflammation and repairs peripheral neuropathy common in CKD | 2–4 mcg/kg | Daily SC |
| BPC-157 BPC-157: reduces renal oxidative stress and fibrosis; nephroprotective via NO pathway; reduces gut-kidney axis inflammation | 250 mcg | Twice daily SC |
| KPV KPV: anti-inflammatory alpha-MSH tripeptide; suppresses renal tubular NF-κB; reduces proteinuria in inflammatory nephropathy | 500 mcg | Daily SC |
| Thymosin Alpha-1 Thymosin Alpha-1: immune modulator; prevents recurrent infections that drive CKD progression; improves vaccine response in immunocompromised patients | 1.6 mg | 3x/week SC |
| Ipamorelin Ipamorelin: preserves lean mass against uremic sarcopenia; lower dose than athletic protocols; avoids fluid retention of full GH | 100–200 mcg | Daily SC |
| NAD+ NAD+: restores mitochondrial function in proximal tubular cells; sirtuin-3 activation reduces tubular ROS and fibrosis signaling | 250–500 mg NMN | Once daily oral |
Free Peptide Guide
Chronic Kidney Disease (CKD) Support Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.
Daily Schedule
Morning
Baseline review and first execution window
Log sleep, energy, and tolerance; complete planned ARA-290 timing if scheduled.
Midday
Adherence and symptom check
Review hydration, workload, and side effects before any changes.
Evening
Recovery closeout and next-day setup
Record outcomes, maintain schedule consistency, and prepare next-day protocol.
Safety
- Escalating side effects or new concerning symptoms require prompt clinical review.
- Avoid abrupt multi-compound changes during unstable periods.
- Maintain regular follow-up with a licensed clinician throughout the cycle.
Not appropriate for unsupervised use or as a replacement for diagnosis and medical care. Use only within a clinician-guided plan.
Who should avoid
- Anyone using this protocol without qualified medical supervision
- People with unstable medical or psychiatric conditions without specialist guidance
- Pregnant or breastfeeding individuals unless explicitly cleared by a physician
Common Mistakes
Changing multiple variables at once
Why it matters: This makes it hard to identify what improved outcomes versus what increased side effects.
How to fix: Keep one-variable changes per review cycle and log response for several days.
Ignoring adherence and recovery fundamentals
Why it matters: Protocol effectiveness drops when sleep, nutrition, and routine consistency are unstable.
How to fix: Protect daily anchors first, then optimize protocol details gradually.
FAQ
How long should Chronic Kidney Disease (CKD) Support Protocol run before reassessment?
A common window is Ongoing; monitor GFR, creatinine, and CBC every 3 months; adjust doses with nephrology oversight, with periodic review of tolerance and objective trends.
Can I increase complexity quickly for faster results?
Usually no. Safer optimization comes from staged changes and clear tracking.
What should I track each day?
Track schedule adherence, symptoms, sleep quality, and any adverse effects in one log.
Key Takeaways
- Consistency with ARA-290 + BPC-157 execution matters more than frequent protocol changes.
- Single-variable adjustments improve safety and decision quality.
- Objective daily tracking supports better long-term outcomes.
Why This Stack Works
CKD creates a vicious cycle of inflammation, oxidative stress, and uremic toxin accumulation that accelerates nephron loss while causing systemic complications. ARA-290 activates erythropoietin receptors in tubular cells to reduce ischemic injury, attenuate inflammation, and simultaneously treat the peripheral neuropathy common in CKD. BPC-157 reduces renal oxidative stress and fibrosis markers, with demonstrated nephroprotective effects in animal models. KPV (alpha-MSH fragment) suppresses renal NF-κB and reduces tubular inflammation without immunosuppressive systemic effects. Thymosin Alpha-1 maintains immune surveillance while preventing infections that accelerate CKD progression. Ipamorelin preserves lean mass against uremic sarcopenia without fluid retention risks of full GH therapy. NAD+ restores mitochondrial function in tubular cells.
Clinical Research
No clinical references were provided for this stack yet.
More General Wellness Stacks
Altitude & Mountaineering Performance Protocol
A protocol for mountaineers, altitude athletes, and competitive cyclists targeting improved hypoxic adaptation, pulmonary vasodilation to prevent HAPE, enhanced oxygen utilization efficiency, and accelerated recovery from altitude-induced tissue stress.
COPD & Pulmonary Rehabilitation Protocol
An adjunctive protocol for individuals with COPD and other chronic lung diseases targeting the airway inflammation, pulmonary fibrosis, mucociliary dysfunction, and systemic muscle wasting that drive progressive respiratory decline.
Chronic Kidney Disease Progression Slowing Protocol
An adjunctive protocol for individuals with CKD stages 2–4 targeting the mitochondrial dysfunction, inflammatory nephropathy, and oxidative damage that drive progressive kidney function decline.
Medical disclaimer: This protocol is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.
Free Peptide Guide
Chronic Kidney Disease (CKD) Support Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.